#6 - Schrodinger (NASDAQ:SDGR)
To this point we’ve focused on large-cap stocks. The last two stocks on this list are small-cap stocks. While they do carry more risk, small-cap stocks have historically led equities out of recessions. The first of these stocks is Schrodinger, Inc. (NASDAQ: SDGR).
The company has an AI-based drug discovery platform. It has an extensive pipeline, and in 2022 received FDA approval to study its novel computer-designed candidate for the treatment of non-Hodgkin lymphomas in clinical trials. Additionally, the company has successfully brought two therapies to market via collaborations.
Like many early-stage biopharma companies, Schrodinger is not yet profitable. That adds an element of risk, mainly when the economy is weak. But the analysts surveyed by MarketBeat give the stock a price target of over $55. That would be a 134% upside from its current level.
About Schrödinger
Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.
Read More - Current Price
- $20.39
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 8 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $32.90 (61.4% Upside)
